As of Friday close, 2seventy bio Inc.’s (NASDAQ:TSVT) stock was down -$0.06, moving down -1.07 percent to $5.56. The average number of shares traded per day over the past five days has been 1,541,440 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.39 fall in that time frame. In the last twenty days, the average volume was 1,537,095, while in the previous 50 days, it was 1,032,208.
Since last month, TSVT stock retreated -47.00%. Shares of the company fell to $5.44 on 08/14/23, the lowest level in the past month. A 52-week high of $17.69 was reached on 02/06/23 after having rallying from a 52-week low of $5.44. Since the beginning of this year, TSVT’s stock price has dropped by -40.66% or -$3.81, and marked a new high 16 times. However, the stock has declined by -68.57% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
TSVT stock investors should be aware that 2seventy bio Inc. (TSVT) stock had its last reported insider trading activity 9 days ago on Aug 10. Kynam Global Healthcare Master, the 10% Owner of the company, purchased of 515,414 shares for $5.92 on Aug 10. It resulted in a $3,049,287 investment by the insider. Kynam Capital Management, LP added 515,414 shares at an average price of $5.92 on Aug 10. The insider now owns 5,953,825 shares following the transaction. On Aug 10, 10% Owner Kynam Capital Management, LP bought 86,414 shares at $5.96 apiece. The transaction was valued at $515,027.
Valuation Metrics
The stock’s beta is 1.35. Besides these, the trailing price-to-sales (P/S) ratio of 2.25, the price-to-book (PB) ratio of 0.60.
Financial Health
In the three months ended June 29, 2seventy bio Inc.’s quick ratio stood at 5.10, while its current ratio was 5.10, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 83.70% percent. Based on annual data, TSVT earned $74.92 million in gross profit and brought in $91.5 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -84.70%. Return on equity (ROE) for the past 12 months was -61.00%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. TSVT’s revenue rose 62.61% to $41.62 million during the quarter, while net income inched up to $36.05 million. While analysts expected 2seventy bio Inc. to report -$1.15 quarterly earnings, the actual figure was -$0.83 per share, beating the consensus estimate by 27.80%. During the quarter, the company generated -$45.75 million in EBITDA. The liabilities of 2seventy bio Inc. were 338.22 million at the end of its most recent quarter ended June 29. The value of shareholders’ equity is $50.47 million.
Technical Picture
This quick technical analysis looks at 2seventy bio Inc.’s (TSVT) price momentum. With a historical volatility rate of 64.37%, the RSI 9-day stood at 20.56% on 18 August.
With respect to its five-day moving average, the current 2seventy bio Inc. price is down by -6.55% percent or -$0.39. At present, TSVT shares trade -46.74% below its 20-day simple moving average and -41.16% percent below its 100-day simple moving average. However, the stock is currently trading approximately -54.09% below its SMA50 and -64.99% below its SMA200.
Stochastic coefficient K was 7.69% and Stochastic coefficient D was 12.79%, while ATR was 0.52. Given the Stochastic reading of 5.45% for the 14-day period, the RSI (14) reading has been calculated as 20.89%. As of today, the MACD Oscillator reading stands at -0.23, while the 14-day reading stands at -0.40.
Analyst Ratings
2seventy bio Inc. downgraded its rating on 2seventy bio Inc. (NASDAQ: TSVT) to an Equal-weight in a note to investors on July 28, 2023. The analysts firm previously had an Overweight rating on the stock.2seventy bio Inc. (TSVT) has been rated Buy by analysts. According to 0 brokerage firms, TSVT is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate 2seventy bio Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $25.00, the current consensus forecast for the stock is $13.00 – $33.00. Based on these forecasts, analysts predict 2seventy bio Inc. (TSVT) will achieve an average price target of $24.33.
